Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET

被引:76
作者
Fanti, Stefano [2 ]
Ambrosini, Valentina [2 ]
Tomassetti, Paola [3 ]
Castellucci, Paolo [2 ]
Montini, Giancarlo [2 ]
Allegri, Vincenzo [2 ]
Grassetto, Gaia [1 ]
Rubello, Domenico [1 ]
Nanni, Cristina [2 ]
Franchi, Roberto [2 ]
机构
[1] Osped S Maria Misericordia, Ist Oncol Veneto, Ctr PET, Unita Operat Med Nucl,IRCCS, I-45100 Rovigo, Veneto, Italy
[2] St Orsola Marcello Malpighi Hosp, Unita Operat Med Nucl, Bologna, Italy
[3] St Orsola Marcello Malpighi Hosp, Unita Operat Med Interna, Bologna, Italy
关键词
Ga-68-DOTA-NOC; PET; Neuroendocrine tumours; NET;
D O I
10.1016/j.biopha.2008.01.010
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
F-18-FDG PET value for the assessment of neuroendocrine tumours (NET) is limited. Preliminary studies indicate that somatostatin receptor PET using Ga-68-DOTA-peptides is more accurate for disease assessment and provide additional data on receptor status, that are crucial for targeted radionuclide therapy. At present, however, few papers investigated the role of Ga-68-DOTA-NOC PET in NET, especially in unusual situations. The purpose of the present study was to evaluate 68Ga-DOTA-NOC for the evaluation of NET of uncommon presentation. Patients with biopsy-proven NET were scheduled for 68Ga-DOTA-NOC PET; we excluded from further evaluation cases with most common NET tumours (gastro-entero-pancreatic and pulmonary localization of primary lesion, MEN syndromes, medullary thyroid carcinoma, pheochromocytomas). PET results were compared with findings of conventional imaging, including CT, ultrasonography, MR and somatostatin receptor scintigraphy; finally PET results were compared with follow-up data with respect to the impact on patient management. Fourteen patients were finally enrolled; primary tumours were located at uterine level (3 cases), prostate (3 cases), ovary (1 case), kidney (1 case), breast (1 case), ear (1 case); also 3 cases of paraganglioma (at neck, abdominal and mediastinum level) and 1 case of lymphoma were included. 68Ga-DOTA-NOC PET was positive, showing at least 1 lesion, in 6/14 cases while 5 cases turned out negative and 2 inconclusive. On a clinical basis, Ga-68-DOTA-NOC provided additional information in comparison to conventional imaging procedures in 7/14 cases, and was considered useful in 12/14 patients, with 8 patients in which 68Ga-DOTA-NOC PET was determinant for patient's management. Although the number of patients studied is limited, our data show that 68Ga-DOTA-NOC can be usefully applied for the evaluation of NET of uncommon presentation; in particular very promising results were obtained in paraganglioma. On the other hand, care has to be paid when studying lesions localized at sites of physiological concentration of the tracer, and in presence of inflammation. (c) 2008 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:667 / 671
页数:5
相关论文
共 33 条
[1]  
Adams S, 1998, EUR J NUCL MED, V25, P79
[2]   Role of 18F-dopa PET/CT imaging in the management of patients with 111In-pentetreotide negative GEP tumours [J].
Ambrosini, Valentina ;
Tomassetti, Paola ;
Rubello, Domenico ;
Campana, Davide ;
Nanni, Cristina ;
Castellucci, Paolo ;
Farsad, Mohsen ;
Montini, Giancarlo ;
Al-Nahhas, Adil ;
Franchi, Roberto ;
Fanti, Stefano .
NUCLEAR MEDICINE COMMUNICATIONS, 2007, 28 (06) :473-477
[3]  
Baum R. P., 2008, V170, P225
[4]   Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours [J].
Buchmann, I. ;
Henze, M. ;
Engelbrecht, S. ;
Eisenhut, M. ;
Runz, A. ;
Schaefer, M. ;
Schilling, T. ;
Haufe, S. ;
Herrmann, T. ;
Haberkorn, U. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 (10) :1617-1626
[5]   The role of PET in localization of neuroendocrine and adrenocortical tumors [J].
Eriksson, B ;
Bergström, M ;
Sundin, A ;
Juhlin, C ;
Örlefors, H ;
Öberg, K ;
Långström, B .
ENDOCRINE HYPERTENSION, 2002, 970 :159-169
[6]   68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors:: Comparison with somatostatin receptor scintigraphy and CT [J].
Gabriel, Michael ;
Decristoforo, Clemens ;
Kendler, Dorota ;
Dobrozemsky, Georg ;
Heute, Dirk ;
Uprimny, Christian ;
Kovacs, Peter ;
Von Guggenberg, Elisabeth ;
Bale, Reto ;
Virgolini, Irene J. .
JOURNAL OF NUCLEAR MEDICINE, 2007, 48 (04) :508-518
[7]   Neuroendocrine tumors of the diffuse neuroendocrine system [J].
Gustafsson, Bjorn I. ;
Kidd, Mark ;
Modlin, Irvin M. .
CURRENT OPINION IN ONCOLOGY, 2008, 20 (01) :1-12
[8]   Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors [J].
Hoegerle, S ;
Altehoefer, C ;
Ghanem, N ;
Koehler, G ;
Waller, CF ;
Scheruebl, H ;
Moser, E ;
Nitzsche, E .
RADIOLOGY, 2001, 220 (02) :373-380
[9]   Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours [J].
Kaltsas, G ;
Rockall, A ;
Papadogias, D ;
Reznek, R ;
Grossman, AB .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2004, 151 (01) :15-27
[10]   Imaging of neuroendocrine tumors: accuracy of helical CT versus SRS [J].
Kumbasar, B ;
Kamel, IR ;
Tekes, A ;
Eng, J ;
Fishman, EK ;
Wahl, RL .
ABDOMINAL IMAGING, 2004, 29 (06) :696-702